For example, selective KCC1 or KCC3 antagonists would be suitable for the therapy of sickle cell anaemia, to prevent overactive transporters from dehydrating erythrocytes and contributing to HbS polymerization (Brown et␣al,2015). This evidence concerns the gene SLC12A4 and sickle cell disease.